An Observational Study to Evaluate Tolerability of Canagliflozin and Sulphonylurea in Type 2 Diabetes Patients During Ramadan
Completed
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2016-04-14
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 379
- Registration Number
- NCT02737657
A Study to Evaluate the Safety and Efficacy of Domperidone in Pediatric Participants With Nausea and Vomiting Due to Acute Gastroenteritis
Phase 3
Terminated
- Conditions
- Gastroenteritis
- Interventions
- First Posted Date
- 2016-03-04
- Last Posted Date
- 2019-03-20
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 10
- Registration Number
- NCT02699385
Pilot Study to Evaluate the Duration of Effects on Simulated Car Driving and Cognitive Performance After a Single Dose of JNJ-42847922, Zolpidem and Placebo in Healthy Participants
- First Posted Date
- 2015-10-19
- Last Posted Date
- 2016-03-24
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 36
- Registration Number
- NCT02578472
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-54175446 in Healthy Male Participants
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: JNJ 54175446 Matching Placebo
- First Posted Date
- 2015-08-05
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 76
- Registration Number
- NCT02515955
A Safety, Efficacy and Biomarker Study of JNJ-42847922 in Participants With Major Depressive Disorder
Phase 1
Completed
- Conditions
- Major Depressive Disorder
- Interventions
- First Posted Date
- 2015-06-19
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 48
- Registration Number
- NCT02476058
A Study to Investigate Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of JNJ-54175446 in Healthy Participants
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2015-06-18
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 76
- Registration Number
- NCT02475148
An Efficacy and Safety Study of a 8 or 12-Week Treatment Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naive and Experienced Participants With Chronic Genotype 4 Hepatitis C Virus Infection
- First Posted Date
- 2014-10-30
- Last Posted Date
- 2016-10-14
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 63
- Registration Number
- NCT02278419
A Study to Assess the Efficacy and Safety of the Combination of Simeprevir and Daclatasvir in Chronic Hepatitis C Genotype 1b-Infected Participants
- First Posted Date
- 2014-10-20
- Last Posted Date
- 2017-03-16
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 106
- Registration Number
- NCT02268864
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42847922 in Healthy Participants
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-09-03
- Last Posted Date
- 2017-01-24
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 40
- Registration Number
- NCT02230878
A Study of Usage of Paliperidone Palmitate in Patients With Schizophrenia in a Hospital Setting
- First Posted Date
- 2013-08-21
- Last Posted Date
- 2015-08-24
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 371
- Registration Number
- NCT01926912